Login / Signup

Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases.

Ting-Hui LiuJheng-Yen WuPo-Yu HuangWan-Hsuan HsuMin-Hsiang ChuangYa-Wen TsaiChih-Cheng LaiChun-Yen Huang
Published in: Expert review of anti-infective therapy (2023)
Our findings indicate that NMV-r to treat COVID-19 could reduce all-cause hospitalization and death in patients with CVDs.
Keyphrases
  • cardiovascular disease
  • coronavirus disease
  • sars cov
  • antiretroviral therapy
  • cardiovascular risk factors
  • type diabetes
  • cardiovascular events
  • coronary artery disease